No, this data was not included in the EUA request.
Post# of 148155
From the pr:
“Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We will expediently submit an update with the above 14-day benefit to the U.S. FDA, Health Canada, and MHRA and will work closely with regulators in other countries. The Company believes this new information bolsters the case for immediate use of leronlimab for critically ill patients.”